Negócios · 31/05/20161 min de leitura
Advisory Committee; Psychopharmacologic Drugs Advisory Committee, Renewal
Tradução automática local · Idioma original da fonte
Resumo
The Food and Drug Administration (FDA) is announcing the renewal of the Psychopharmacologic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Psychopharmacologic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the June 4, 2018.